RASD2 and thyroid gland carcinoma: Our findings revealed that RASD2 promotes thyroid cancer progression through enhanced cellular proliferation, invasion, and glycolytic metabolism, while miR‐485‐5p acts as a tumor suppressor by directly targeting RASD2.